Compare Humana Inc (HUM) vs Centrus Energy Corp (LEU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Centrus Energy Corp — how do they compare? Humana Inc trades at $437.2 (market cap $47.61B), while Centrus Energy Corp trades at $144.07 (market cap $3.01B). The key difference: Humana Inc is far larger — about 15.8× Centrus Energy Corp's market cap, and Humana Inc pays a 0.89% dividend while Centrus Energy Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and Centrus Energy Corp for 29 Days on average.
| HUM | LEU | |
|---|---|---|
Market Cap | $47.61B | $3.01B |
Volume | 1,827,332 | 868,801 |
Sector | Health | Energy |
52-Week High | $409.85 | $436.00 |
52-Week Low | $163.67 | $138.18 |
Typical Hold Time | 53 Days | 29 Days |
Enterprise Value | $54.97B | $2.32B |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $387.12, down 4.24% today, but maintains a bullish technical outlook with strong institutional support. The stock shows mixed fundamentals with revenue growth to $129.66B in 2025 but declining profit margins at 0.88%. Recent analyst upgrades, including Barclays' $515 target on September 25, 2026, highlight optimism despite ongoing Medicare Advantage plan adjustments affecting member transitions.
Investment outlook remains cautiously optimistic with a consensus price target of $432.63 offering 12% upside. Risks include margin compression, regulatory scrutiny from Medicare billing practices, and competitive pressures in managed care. The company's strong cash position of $20.44B and consistent dividend payments provide stability amid enrollment volatility.
Centrus Energy (LEU) trades at $147.14, down 4.38% on the day, with a neutral technical signal. The company reported Q2 2026 EPS of $0.77, beating estimates, but faces declining profitability margins into 2026. Recent news highlights its strategic position as a supplier of High-Assay Low-Enriched Uranium (HALEU), benefiting from U.S. nuclear energy growth and partnerships, though execution risks remain high.
Outlook is mixed: strong analyst consensus price target of $218.10 implies significant upside, supported by nuclear sector tailwinds and new contracts. However, high valuation multiples (P/E 77.85), volatile cash flows, and margin compression pose risks. Investors should weigh growth potential against execution challenges in a capital-intensive industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Centrus Energy Corp
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →
